Middle East and Africa Prophylaxis of Organ Rejection Market Analysis, Demand & Growth Forecast

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 BY CAUSE SEGMENT LIFELINE CURVE

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 MARKET END USER COVERAGE GRID

2.11 SECONDARY SOURCES

3 EXECUTIVE SUMMARY

4 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION: EPIDEMIOLOGY SNAPSHOT

5 MARKET OVERVIEW

5.1 DRIVERS

5.1.1 RISE IN PREVALENCE OF ORGAN TRANSPLANTATIONS

5.1.2 RISE IN CHRONIC DISEASES

5.1.3 RISE IN CLINICAL TRIALS

5.1.4 RISE IN RECIPIENT PATIENTS

5.1.5 PRODUCT APPROVALS

5.2 RESTRAINTS

5.2.1 RISE IN COST OF TRANSPLANTATION PROCEDURE

5.2.2 LACK OF AWARENESS ABOUT ORGAN TRANSPLANTATION

5.2.3 RISKS INCLUDED WITH THE PATIENT RECEIVES TRANSPLANTED ORGAN

5.2.4 ETHICAL ISSUES RELATED TO ORGAN TRANSPLANTATION

5.3 OPPORTUNITIES

5.3.1 RISE IN RESEARCH AND DEVELOPMENTS

5.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS

5.3.3 RISE IN USE OF IMMUNOSUPPRESSANT

5.4 CHALLENGES

5.4.1 SHORTAGE OF SKILLED PROFESSIONALS REQUIRED FOR THE USE OF PROPHYLAXIS OF ORGAN REJECTION

5.4.2 STRINGENT REGULATIONS

6 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE

6.1 OVERVIEW

6.2 EPIDEMIOLOGIC EXPOSURE

6.2.1 HOSPITAL EXPOSURE

6.2.2 COMMUNITY EXPOSURE

6.3 ANTIBACTERIAL PROPHYLAXIS

6.3.1 POST-TRANSPLANT PROPHYLAXIS

6.3.2 PERIOPERATIVE ANTIBACTERIAL PROPHYLAXIS

6.4 PROPHYLAXIS AGAINST OTHER PATHOGENS

6.5 OTHERS

7 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT

7.1 OVERVIEW

7.2 OUTPATIENT IMMUNOSUPPRESSANT

7.2.1 CALCINEURIN INHIBITORS

7.2.1.1 CYCLOSPORINE

7.2.1.2 TACROLIMUS

7.2.1.2.1 IMMEDIATE RELEASE

7.2.1.2.2 EXTENDED RELEASE

7.2.2 CORTICOSTEROIDS

7.2.2.1 METHYLPREDNISOLONE

7.2.2.2 PREDNISONE

7.2.2.3 OTHERS

7.2.3 MYCOPHENOLIC ACIDS

7.2.3.1 MYCOPHENOLATE MOFETIL

7.2.3.2 MYCOPHENOLATE SODIUM

7.2.4 MTOR INHIBITORS

7.2.4.1 SIROLIMUS

7.2.4.2 EVEROLIMUS

7.2.5 AZATHIOPRINE

7.2.6 OTHERS

7.3 INPATIENT IMMUNOSUPPRESSANT

7.3.1 BELATACEPT

7.3.2 BASILIXIMAB

7.3.3 OTHERS

7.4 OTHERS

7.4.1 ERYTHROPOIESIS-STIMULATING AGENTS

7.4.1.1 ERYTHROPOIETIN

7.4.1.2 DARBEPOETIN

7.4.2 ANTI-VIRAL AGENTS

7.4.2.1 VALGANCICLOVIR

7.4.2.2 LAMIVUDINE

7.4.2.3 ADEFOVIR

7.4.2.4 OTHERS

7.4.3 OTHERS

8 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION

8.1 OVERVIEW

8.2 ORAL

8.2.1 TABLET

8.2.1.1 IMMEDIATE RELEASE

8.2.1.2 EXTENDED-RELEASE

8.2.2 ORAL SOLUTION

8.2.3 OTHERS

8.3 INTRAVENOUS

9 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN

9.1 OVERVIEW

9.2 KIDNEY

9.3 LIVER

9.4 HEART

9.5 LUNG

9.6 OTHERS

10 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE

10.1 OVERVIEW

10.2 ADULTS

10.3 PEDIATRIC

11 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS

11.3 CLINICS

11.4 HOME HEALTHCARE

11.5 OTHERS

12 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 DIRECT TENDERS

12.3 PHARMACY STORES

12.3.1 HOSPITAL PHARMACY

12.3.2 RETAIL PHARMACY

12.3.3 ONLINE PHARMACY

12.4 OTHERS

13 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION

13.1 MIDDLE EAST AND AFRICA

13.1.1 SAUDI ARABIA

13.1.2 SOUTH AFRICA

13.1.3 ISRAEL

13.1.4 KUWAIT

13.1.5 U.A.E

13.1.6 REST OF MIDDLE EAST AND AFRICA

14 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA

15 QUESTIONNAIRE

16 RELATED REPORTS

List of Table

TABLE 1 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 2 MIDDLE EAST & AFRICA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 3 MIDDLE EAST & AFRICA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 4 MIDDLE EAST & AFRICA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 MIDDLE EAST & AFRICA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 6 MIDDLE EAST & AFRICA PROPHYLAXIS AGAINST OTHER PATHOGENS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 MIDDLE EAST & AFRICA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 9 MIDDLE EAST & AFRICA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 MIDDLE EAST & AFRICA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 25 MIDDLE EAST & AFRICA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA INTRAVENOUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 28 MIDDLE EAST & AFRICA KIDNEY IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 MIDDLE EAST & AFRICA LIVER IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 MIDDLE EAST & AFRICA HEART IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA LUNG IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 34 MIDDLE EAST & AFRICA ADULTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 35 MIDDLE EAST & AFRICA PEDIATRIC IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 36 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 37 MIDDLE EAST & AFRICA HOSPITALS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 38 MIDDLE EAST & AFRICA CLINICS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 39 MIDDLE EAST & AFRICA HOME HEALTHCARE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 40 MIDDLE EAST & AFRICA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 41 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 42 MIDDLE EAST & AFRICA DIRECT TENDERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 43 MIDDLE EAST & AFRICA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 44 MIDDLE EAST & AFRICA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 45 MIDDLE EAST & AFRICA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 46 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

TABLE 47 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 48 MIDDLE EAST AND AFRICA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 49 MIDDLE EAST AND AFRICA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 50 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 51 MIDDLE EAST AND AFRICA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 52 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 53 MIDDLE EAST AND AFRICA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 54 MIDDLE EAST AND AFRICA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 55 MIDDLE EAST AND AFRICA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 56 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 57 MIDDLE EAST AND AFRICA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 58 MIDDLE EAST AND AFRICA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 59 MIDDLE EAST AND AFRICA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 60 MIDDLE EAST AND AFRICA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 61 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 62 MIDDLE EAST AND AFRICA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 63 MIDDLE EAST AND AFRICA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 64 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 65 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 66 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 67 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 68 MIDDLE EAST AND AFRICA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 69 SAUDI ARABIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 70 SAUDI ARABIA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 71 SAUDI ARABIA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 72 SAUDI ARABIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 73 SAUDI ARABIA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 74 SAUDI ARABIA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 75 SAUDI ARABIA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 76 SAUDI ARABIA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 77 SAUDI ARABIA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 78 SAUDI ARABIA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 79 SAUDI ARABIA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 80 SAUDI ARABIA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 81 SAUDI ARABIA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 82 SAUDI ARABIA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 83 SAUDI ARABIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 84 SAUDI ARABIA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 85 SAUDI ARABIA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 86 SAUDI ARABIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 87 SAUDI ARABIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 88 SAUDI ARABIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 89 SAUDI ARABIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 90 SAUDI ARABIA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 91 SOUTH AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 92 SOUTH AFRICA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 93 SOUTH AFRICA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 94 SOUTH AFRICAPROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 95 SOUTH AFRICA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 96 SOUTH AFRICA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 97 SOUTH AFRICA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 98 SOUTH AFRICA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 99 SOUTH AFRICA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 100 SOUTH AFRICA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 101 SOUTH AFRICA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 102 SOUTH AFRICA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 103 SOUTH AFRICA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 104 SOUTH AFRICA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 105 SOUTH AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 106 SOUTH AFRICA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 107 SOUTH AFRICA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 108 SOUTH AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 109 SOUTH AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 110 SOUTH AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 111 SOUTH AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 112 SOUTH AFRICA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 113 ISRAEL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 114 ISRAEL EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 115 ISRAEL ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 116 ISRAEL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 117 ISRAEL OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 118 ISRAEL CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 119 ISRAEL TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 120 ISRAEL MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 121 ISRAEL MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 122 ISRAEL CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 123 ISRAEL INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 124 ISRAEL OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 125 ISRAEL ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 126 ISRAEL ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 127 ISRAEL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 128 ISRAEL ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 129 ISRAEL TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 130 ISRAEL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 131 ISRAEL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 132 ISRAEL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 133 ISRAEL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 134 ISRAEL PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 135 KUWAIT PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 136 KUWAIT EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 137 KUWAIT ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 138 KUWAIT PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 139 KUWAIT OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 140 KUWAIT CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 141 KUWAIT TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 142 KUWAIT MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 143 KUWAIT MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 144 KUWAIT CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 145 KUWAIT INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 146 KUWAIT OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 147 KUWAIT ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 148 KUWAIT ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 149 KUWAIT PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 150 KUWAIT ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 151 KUWAIT TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 152 KUWAIT PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 153 KUWAIT PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 154 KUWAIT PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 155 KUWAIT PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 156 KUWAIT PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 157 U.A.E PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 158 U.A.E EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 159 U.A.E ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 160 U.A.E PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 161 U.A.E OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 162 U.A.E CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 163 U.A.E TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 164 U.A.E MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 165 U.A.E MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 166 U.A.E CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 167 U.A.E INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 168 U.A.E OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 169 U.A.E ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 170 U.A.E ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 171 U.A.E PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 172 U.A.E ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 173 U.A.E TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 174 U.A.E PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 175 U.A.E PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 176 U.A.E PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 177 U.A.E PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 178 U.A.E PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 179 REST OF MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

List of Figure

FIGURE 1 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: DBMR POSITION GRID

FIGURE 8 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: END USER COVERAGE GRID

FIGURE 10 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: SEGMENTATION

FIGURE 11 NORTH AMERICA IS EXPECTED TO DOMINATE THE MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 INCREASED PREVALENCE OF ORGAN TRANSPLANTATION, RISE IN RECIPIENT PATIENTS, AND PRODUCT APPPROVALS ARE EXPECTED TO DRIVE MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET FROM 2022 TO 2029

FIGURE 13 EPIDEMIOLOGIC EXPOSURE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET FROM 2022 & 2029

FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR PROPHYLAXIS OF ORGAN REJECTION MANUFACTURERS IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 15 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION: INCIDENCE, 2021

FIGURE 16 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION: INCIDENCE REGIONAL LEVEL, 2021

FIGURE 17 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION: PREVALENCE (2018-2021) AT REGIONAL LEVEL SNAPSHOT

FIGURE 18 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION: SURVIVAL OF PATIENT SNAPSHOT

FIGURE 19 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET

FIGURE 20 INCREASE COUNT OF KIDNEY TRANSPLANTATIONS IN THE U.S., 2020

FIGURE 21 TOTAL NUMBER OF ORGAN TRANSPLANTATION IN THE MIDDLE EAST & AFRICA SCENARIO, 2020

FIGURE 22 TOTAL NUMBER OF PATIENTS ON WAITING LIST VS TRANSPLANTS PERFORMED BY ORGAN IN 2020

FIGURE 23 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY CAUSE, 2021

FIGURE 24 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY CAUSE, 2020-2029 (USD MILLION)

FIGURE 25 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY CAUSE, CAGR (2022-2029)

FIGURE 26 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY CAUSE, LIFELINE CURVE

FIGURE 27 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY TREATMENT, 2021

FIGURE 28 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY TREATMENT, 2020-2029 (USD MILLION)

FIGURE 29 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY TREATMENT, CAGR (2022-2029)

FIGURE 30 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 31 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ROUTE OF ADMINISTRATION, 2021

FIGURE 32 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

FIGURE 33 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 34 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 35 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ORGAN, 2021

FIGURE 36 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ORGAN, 2020-2029 (USD MILLION)

FIGURE 37 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ORGAN, CAGR (2022-2029)

FIGURE 38 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ORGAN, LIFELINE CURVE

FIGURE 39 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY PATIENT TYPE, 2021

FIGURE 40 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY PATIENT TYPE, 2020-2029 (USD MILLION)

FIGURE 41 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY PATIENT TYPE, CAGR (2022-2029)

FIGURE 42 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY PATIENT TYPE, LIFELINE CURVE

FIGURE 43 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY END USER, 2021

FIGURE 44 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY END USER, 2020-2029 (USD MILLION)

FIGURE 45 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY END USER, CAGR (2022-2029)

FIGURE 46 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY END USER, LIFELINE CURVE

FIGURE 47 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 48 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

FIGURE 49 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 50 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 51 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: SNAPSHOT (2021)

FIGURE 52 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY COUNTRY (2021)

FIGURE 53 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY COUNTRY (2022 & 2029)

FIGURE 54 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY COUNTRY (2021 & 2029)

FIGURE 55 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY CAUSE (2022-2029)

FIGURE 56 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: COMPANY SHARE 2021 (%)

Frequently Asked Questions

What are the primary segments covered in the Middle East And Africa Prophylaxis Of Organ Rejection Market report?

The market is segmented based on , By Cause (Epidemiologic Exposure, Antibacterial Prophylaxis, Prophylaxis Against Other Pathogens And Others), Treatment (Outpatient Immunosuppressant, Inpatient Immunosuppressant And Others), Route Of Administration (Oral, Intravenous), Organ (Kidney, Liver, Heart, Lung, Others), Patient Type (Pediatric, Adults), End User (Hospitals, Clinic Home Healthcare And Others), Distribution Channel (Direct Tender, Pharmacy Stores And Others), Country (Saudi Arabia, South Africa, Israel, Kuwait, UAE And Rest Of Middle East & Africa), Market Trends And Forecast To 2029. .

What is the current market size of the Middle East And Africa Prophylaxis Of Organ Rejection Market?

The Middle East And Africa Prophylaxis Of Organ Rejection Market size was valued at USD 59.81 USD Million in 2021.

What is the expected growth rate of the Middle East And Africa Prophylaxis Of Organ Rejection Market?

The Middle East And Africa Prophylaxis Of Organ Rejection Market is projected to grow at a CAGR of 2% during the forecast period of 2022 to 2029.